QNRX vs. DYNT, TNON, NMRD, INVO, AEMD, BJDX, IONM, STSS, AFIB, and UTRS
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Dynatronics (DYNT), Tenon Medical (TNON), Nemaura Medical (NMRD), INVO Bioscience (INVO), Aethlon Medical (AEMD), Bluejay Diagnostics (BJDX), Assure (IONM), Sharps Technology (STSS), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "surgical & medical instruments" industry.
Quoin Pharmaceuticals (NASDAQ:QNRX) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 3.3% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of Dynatronics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Quoin Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 534.92%. Dynatronics has a consensus target price of $3.80, suggesting a potential upside of 560.41%. Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than Quoin Pharmaceuticals.
Dynatronics has higher revenue and earnings than Quoin Pharmaceuticals. Dynatronics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Dynatronics had 1 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 2 mentions for Dynatronics and 1 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.67 beat Dynatronics' score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.
Dynatronics received 304 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 50.99% of users gave Dynatronics an outperform vote.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Dynatronics' net margin of -14.13%. Dynatronics' return on equity of -54.88% beat Quoin Pharmaceuticals' return on equity.
Quoin Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Dynatronics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Summary
Dynatronics beats Quoin Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
